Company attributes
Other attributes
DNA Script is a company that provides solutions to genomic research projects and personalized medicine through biological and enzyme engineering. It produces synthetic DNA using enzymatic synthesis for use in drug discovery, industrial biotechnology, food technology, and nanotechnologies. The company is headquartered in Paris, France and was founded in 2014 by Thomas Ybert, Sylvain Gariel, and Xavier Gordon.
In April 2018, DNA Script announced that it has been awarded $5.5 million in grant funding from the European Commission and French investment bank Bpifrance.
In September 2017, DNA Script closed their Series A round. It was led by Illumina Ventures and joined by Merck Ventures and existing investors Sofinnova Partners, Kurma Partners, and Idinvest Partners. In total they raised a total of €11M.
